OMARKERS AS SURROGATE ENDPOINTS IN CLINICAL TRIALS

被引：0
|
作者：
Rosenkranz, Bernd [1 ]
机构：
[1] Univ Stellenbosch, Dept Med, Div Pharmacol, ZA-7505 Cape Town, South Africa
来源：
MEDICINAL CHEMISTRY RESEARCH | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Surrogate Endpoints in Clinical Trials
    Elliott, Michael R.
    ANNUAL REVIEW OF STATISTICS AND ITS APPLICATION, 2023, 10 : 75 - 96
  • [2] Clinical trials: Surrogate endpoints or hard endpoints?
    Kuller, LH
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (2A): : 59E - 61E
  • [3] SURROGATE ENDPOINTS IN CLINICAL-TRIALS
    FRIEDMAN, L
    YUSUF, S
    CONTROLLED CLINICAL TRIALS, 1985, 6 (03): : 222 - 222
  • [4] Biomarkers and surrogate endpoints in clinical trials
    Fleming, Thomas R.
    Powers, John H.
    STATISTICS IN MEDICINE, 2012, 31 (25) : 2973 - 2984
  • [5] Surrogate endpoints in randomized cardiovascular clinical trials
    Domanski, Michael
    Pocock, Stuart
    Bernaud, Corine
    Borer, Jeffrey
    Geller, Nancy
    Revkin, James
    Zannad, Faiez
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 (04) : 411 - 413
  • [6] SURROGATE ENDPOINTS IN CLINICAL-TRIALS - CANCER
    ELLENBERG, SS
    HAMILTON, JM
    STATISTICS IN MEDICINE, 1989, 8 (04) : 405 - 413
  • [7] Biomarkers and surrogate endpoints in glaucoma clinical trials
    Medeiros, Felipe A.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (05) : 599 - 603
  • [8] A perspective on surrogate endpoints in controlled clinical trials
    Molenberghs, G
    Burzykowski, T
    Alonso, A
    Buyse, M
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2004, 13 (03) : 177 - 206
  • [9] The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases
    Lonn, E
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) : 497 - 508
  • [10] Cancer prevention: biomarkers and surrogate endpoints in clinical trials
    Greenberg, ER
    Hong, WK
    BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : 217 - 232
12345